{"id":55699,"date":"2023-04-11T17:07:18","date_gmt":"2023-04-11T15:07:18","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/kiyatec-to-present-two-posters-highlighting-the-companys-work-in-ex-vivo-immuno-oncology-at-the-2023-aacr-annual-meeting-april-14-19-in-orlando-fl\/"},"modified":"2023-04-11T17:07:18","modified_gmt":"2023-04-11T15:07:18","slug":"kiyatec-to-present-two-posters-highlighting-the-companys-work-in-ex-vivo-immuno-oncology-at-the-2023-aacr-annual-meeting-april-14-19-in-orlando-fl","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/kiyatec-to-present-two-posters-highlighting-the-companys-work-in-ex-vivo-immuno-oncology-at-the-2023-aacr-annual-meeting-april-14-19-in-orlando-fl\/","title":{"rendered":"Kiyatec to present two posters highlighting the company\u2019s work in ex vivo immuno-oncology at the 2023 AACR Annual Meeting April 14-19, in Orlando, FL"},"content":{"rendered":"<div>\n<p>GREENVILLE, S.C.&#8211;(BUSINESS WIRE)&#8211;Kiyatec, the leader in clinically correlated, published functional precision oncology technology, today announced that two abstracts were accepted for poster presentations at the American Association for Cancer Research (AACR) Annual Meeting to be held in Orlando, Florida from April 14 \u2013 19, 2023.<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20230411005754\/en\/1760022\/5\/Kiyatec_horz_logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230411005754\/en\/1760022\/21\/Kiyatec_horz_logo.jpg\"><\/a><\/p>\n<p>\nKiyatec\u2019s clinical and pre-clinical technology platforms, 3D Predict\u2122 and KIYA-PREDICT\u2122, respectively, are leading the functional precision oncology space with published evidence of predictive response correlated to clinical outcomes. The two abstracts accepted for presentation at the conference highlight the companies work in ex vivo immune-oncology applications for pre-clinical drug development, including multiple mechanisms of action, utilization of ex vivo PDX, and development of advanced organoid technology. The ex vivo PDX work features an ongoing collaboration with investigators from XenoSTART.<\/p>\n<p>\n\u201cThe work being presented highlights the application of Kiyatec\u2019s technologies for the development and testing of multiple types of immunotherapies,\u201d said Tessa DesRochers, Kiyatec\u2019s Chief Scientific Officer. \u201cOur technology platforms allow for testing of I\/O agents on primary patient tissue and ex vivo PDX tissue, providing expanded, more relevant avenues for drug development in immuno-oncology.\u201d<\/p>\n<p>\nSession titles and information for the abstracts are listed below and are also available on the AACR online itinerary planner. Kiyatec will exhibit it\u2019s preclinical service offerings at AACR at <b>Booth #419.<\/b><\/p>\n<p>\n<b>Kiyatec presentation schedule:<\/b><\/p>\n<p>\n<b>Preclinical testing of therapeutic biologics using patient-derived 3D Spheroids<\/b><\/p>\n<p>\nClinical Research Excluding Trials<\/p>\n<p>\nMonday, April 17<sup>th<\/sup> 9:00am \u2013 12:30pm<\/p>\n<p>\n<b>Perfused patient-derived tumor organoid models with autologous immune cells for preclinical drug development<\/b><\/p>\n<p>\nTumor Organoids for Therapeutic Testing<\/p>\n<p>\nSunday, April 16<sup>th<\/sup> 1:30pm \u2013 5:00pm<\/p>\n<p>\n<b>About Kiyatec<\/b><\/p>\n<p>\nKiyatec is a functional precision oncology company that provides confidence to patients, oncologists, and pharmaceutical companies in their life-changing cancer therapy decisions by measuring the response of individual patient\u2019s live tumor cells to different cancer therapies. With a patient-first focus and cutting-edge science, Kiyatec is advancing a new era of cancer treatment success, where patients routinely respond, and effective new drugs are frequently approved.<\/p>\n<p>\nThe company\u2019s pre-clinical drug development service works with leading biopharmaceutical companies to unlock response dynamics and help de-risk investigational drug candidates across most solid tumor types. The company\u2019s clinical service offers clinical tests for high-grade glioma, the most common and lethal tumor of the central nervous system. The company\u2019s expanding pipeline of tests includes a focus on ovarian cancer, breast cancer, and non-small cell lung cancer in its CLIA-certified lab.<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>Matt Gevaert, PhD<\/b><br \/>Chief Executive Officer<br \/>\n<br \/>864-502-2013<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>GREENVILLE, S.C.&#8211;(BUSINESS WIRE)&#8211;Kiyatec, the leader in clinically correlated, published functional precision oncology technology, today announced that two abstracts were accepted for poster presentations at the American Association for Cancer Research (AACR) Annual Meeting to be held in Orlando, Florida from April 14 \u2013 19, 2023. Kiyatec\u2019s clinical and pre-clinical technology platforms, 3D Predict\u2122 and KIYA-PREDICT\u2122, &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/kiyatec-to-present-two-posters-highlighting-the-companys-work-in-ex-vivo-immuno-oncology-at-the-2023-aacr-annual-meeting-april-14-19-in-orlando-fl\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-55699","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Kiyatec to present two posters highlighting the company\u2019s work in ex vivo immuno-oncology at the 2023 AACR Annual Meeting April 14-19, in Orlando, FL - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/kiyatec-to-present-two-posters-highlighting-the-companys-work-in-ex-vivo-immuno-oncology-at-the-2023-aacr-annual-meeting-april-14-19-in-orlando-fl\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kiyatec to present two posters highlighting the company\u2019s work in ex vivo immuno-oncology at the 2023 AACR Annual Meeting April 14-19, in Orlando, FL - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"GREENVILLE, S.C.&#8211;(BUSINESS WIRE)&#8211;Kiyatec, the leader in clinically correlated, published functional precision oncology technology, today announced that two abstracts were accepted for poster presentations at the American Association for Cancer Research (AACR) Annual Meeting to be held in Orlando, Florida from April 14 \u2013 19, 2023. Kiyatec\u2019s clinical and pre-clinical technology platforms, 3D Predict\u2122 and KIYA-PREDICT\u2122, ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/kiyatec-to-present-two-posters-highlighting-the-companys-work-in-ex-vivo-immuno-oncology-at-the-2023-aacr-annual-meeting-april-14-19-in-orlando-fl\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-11T15:07:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230411005754\/en\/1760022\/21\/Kiyatec_horz_logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kiyatec-to-present-two-posters-highlighting-the-companys-work-in-ex-vivo-immuno-oncology-at-the-2023-aacr-annual-meeting-april-14-19-in-orlando-fl\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kiyatec-to-present-two-posters-highlighting-the-companys-work-in-ex-vivo-immuno-oncology-at-the-2023-aacr-annual-meeting-april-14-19-in-orlando-fl\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Kiyatec to present two posters highlighting the company\u2019s work in ex vivo immuno-oncology at the 2023 AACR Annual Meeting April 14-19, in Orlando, FL\",\"datePublished\":\"2023-04-11T15:07:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kiyatec-to-present-two-posters-highlighting-the-companys-work-in-ex-vivo-immuno-oncology-at-the-2023-aacr-annual-meeting-april-14-19-in-orlando-fl\\\/\"},\"wordCount\":432,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kiyatec-to-present-two-posters-highlighting-the-companys-work-in-ex-vivo-immuno-oncology-at-the-2023-aacr-annual-meeting-april-14-19-in-orlando-fl\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230411005754\\\/en\\\/1760022\\\/21\\\/Kiyatec_horz_logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kiyatec-to-present-two-posters-highlighting-the-companys-work-in-ex-vivo-immuno-oncology-at-the-2023-aacr-annual-meeting-april-14-19-in-orlando-fl\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kiyatec-to-present-two-posters-highlighting-the-companys-work-in-ex-vivo-immuno-oncology-at-the-2023-aacr-annual-meeting-april-14-19-in-orlando-fl\\\/\",\"name\":\"Kiyatec to present two posters highlighting the company\u2019s work in ex vivo immuno-oncology at the 2023 AACR Annual Meeting April 14-19, in Orlando, FL - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kiyatec-to-present-two-posters-highlighting-the-companys-work-in-ex-vivo-immuno-oncology-at-the-2023-aacr-annual-meeting-april-14-19-in-orlando-fl\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kiyatec-to-present-two-posters-highlighting-the-companys-work-in-ex-vivo-immuno-oncology-at-the-2023-aacr-annual-meeting-april-14-19-in-orlando-fl\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230411005754\\\/en\\\/1760022\\\/21\\\/Kiyatec_horz_logo.jpg\",\"datePublished\":\"2023-04-11T15:07:18+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kiyatec-to-present-two-posters-highlighting-the-companys-work-in-ex-vivo-immuno-oncology-at-the-2023-aacr-annual-meeting-april-14-19-in-orlando-fl\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kiyatec-to-present-two-posters-highlighting-the-companys-work-in-ex-vivo-immuno-oncology-at-the-2023-aacr-annual-meeting-april-14-19-in-orlando-fl\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kiyatec-to-present-two-posters-highlighting-the-companys-work-in-ex-vivo-immuno-oncology-at-the-2023-aacr-annual-meeting-april-14-19-in-orlando-fl\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230411005754\\\/en\\\/1760022\\\/21\\\/Kiyatec_horz_logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230411005754\\\/en\\\/1760022\\\/21\\\/Kiyatec_horz_logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kiyatec-to-present-two-posters-highlighting-the-companys-work-in-ex-vivo-immuno-oncology-at-the-2023-aacr-annual-meeting-april-14-19-in-orlando-fl\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kiyatec to present two posters highlighting the company\u2019s work in ex vivo immuno-oncology at the 2023 AACR Annual Meeting April 14-19, in Orlando, FL\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Kiyatec to present two posters highlighting the company\u2019s work in ex vivo immuno-oncology at the 2023 AACR Annual Meeting April 14-19, in Orlando, FL - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/kiyatec-to-present-two-posters-highlighting-the-companys-work-in-ex-vivo-immuno-oncology-at-the-2023-aacr-annual-meeting-april-14-19-in-orlando-fl\/","og_locale":"en_US","og_type":"article","og_title":"Kiyatec to present two posters highlighting the company\u2019s work in ex vivo immuno-oncology at the 2023 AACR Annual Meeting April 14-19, in Orlando, FL - Pharma Trend","og_description":"GREENVILLE, S.C.&#8211;(BUSINESS WIRE)&#8211;Kiyatec, the leader in clinically correlated, published functional precision oncology technology, today announced that two abstracts were accepted for poster presentations at the American Association for Cancer Research (AACR) Annual Meeting to be held in Orlando, Florida from April 14 \u2013 19, 2023. Kiyatec\u2019s clinical and pre-clinical technology platforms, 3D Predict\u2122 and KIYA-PREDICT\u2122, ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/kiyatec-to-present-two-posters-highlighting-the-companys-work-in-ex-vivo-immuno-oncology-at-the-2023-aacr-annual-meeting-april-14-19-in-orlando-fl\/","og_site_name":"Pharma Trend","article_published_time":"2023-04-11T15:07:18+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230411005754\/en\/1760022\/21\/Kiyatec_horz_logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/kiyatec-to-present-two-posters-highlighting-the-companys-work-in-ex-vivo-immuno-oncology-at-the-2023-aacr-annual-meeting-april-14-19-in-orlando-fl\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/kiyatec-to-present-two-posters-highlighting-the-companys-work-in-ex-vivo-immuno-oncology-at-the-2023-aacr-annual-meeting-april-14-19-in-orlando-fl\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Kiyatec to present two posters highlighting the company\u2019s work in ex vivo immuno-oncology at the 2023 AACR Annual Meeting April 14-19, in Orlando, FL","datePublished":"2023-04-11T15:07:18+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/kiyatec-to-present-two-posters-highlighting-the-companys-work-in-ex-vivo-immuno-oncology-at-the-2023-aacr-annual-meeting-april-14-19-in-orlando-fl\/"},"wordCount":432,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/kiyatec-to-present-two-posters-highlighting-the-companys-work-in-ex-vivo-immuno-oncology-at-the-2023-aacr-annual-meeting-april-14-19-in-orlando-fl\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230411005754\/en\/1760022\/21\/Kiyatec_horz_logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/kiyatec-to-present-two-posters-highlighting-the-companys-work-in-ex-vivo-immuno-oncology-at-the-2023-aacr-annual-meeting-april-14-19-in-orlando-fl\/","url":"https:\/\/pharma-trend.com\/en\/kiyatec-to-present-two-posters-highlighting-the-companys-work-in-ex-vivo-immuno-oncology-at-the-2023-aacr-annual-meeting-april-14-19-in-orlando-fl\/","name":"Kiyatec to present two posters highlighting the company\u2019s work in ex vivo immuno-oncology at the 2023 AACR Annual Meeting April 14-19, in Orlando, FL - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/kiyatec-to-present-two-posters-highlighting-the-companys-work-in-ex-vivo-immuno-oncology-at-the-2023-aacr-annual-meeting-april-14-19-in-orlando-fl\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/kiyatec-to-present-two-posters-highlighting-the-companys-work-in-ex-vivo-immuno-oncology-at-the-2023-aacr-annual-meeting-april-14-19-in-orlando-fl\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230411005754\/en\/1760022\/21\/Kiyatec_horz_logo.jpg","datePublished":"2023-04-11T15:07:18+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/kiyatec-to-present-two-posters-highlighting-the-companys-work-in-ex-vivo-immuno-oncology-at-the-2023-aacr-annual-meeting-april-14-19-in-orlando-fl\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/kiyatec-to-present-two-posters-highlighting-the-companys-work-in-ex-vivo-immuno-oncology-at-the-2023-aacr-annual-meeting-april-14-19-in-orlando-fl\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/kiyatec-to-present-two-posters-highlighting-the-companys-work-in-ex-vivo-immuno-oncology-at-the-2023-aacr-annual-meeting-april-14-19-in-orlando-fl\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230411005754\/en\/1760022\/21\/Kiyatec_horz_logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230411005754\/en\/1760022\/21\/Kiyatec_horz_logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/kiyatec-to-present-two-posters-highlighting-the-companys-work-in-ex-vivo-immuno-oncology-at-the-2023-aacr-annual-meeting-april-14-19-in-orlando-fl\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Kiyatec to present two posters highlighting the company\u2019s work in ex vivo immuno-oncology at the 2023 AACR Annual Meeting April 14-19, in Orlando, FL"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55699","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=55699"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55699\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=55699"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=55699"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=55699"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}